Lifecore Biomedical

LFCR

Market cap $296M

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore's participation are as follows:

Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Christine Rains - William Blair & Company L.L.C., Research Division Presentation Stephanie Diaz Vida Strategic Partners, Inc. Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter 2025 Earnings results for the 3 months ended September 30, 2025.

Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.53 per share a year ago.

--  Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the three months ended September 30, 2025.

CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close.

Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company's activities at these events are as follows:

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  LifeCore between October 7, 2020, and March 19, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.